Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Celldex Therapeutics, Inc.
Celldex Reports First Quarter 2009 Financial Results
May 20th, 2009
Celldex Therapeutics, Inc. (NASDAQ: CLDX) reported financial results for the first quarter ended March 31, 2009. Celldex reported a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009 compared to a net loss of $22.1 million, or $2.19 per share, for the first quarter of 2008. On March 7, 2008, privately-held Celldex Therapeutics, Inc. completed its merger with a wholly-owned subsidiary of AVANT Immunotherapeutics, Inc. and, effective October 1, 2008, AVANT changed its name to Celldex Therapeutics, Inc. As discussed in further detail later in this release, the decrease in net loss between the three-month periods was primarily due to increased...
Source: Vaccine Weekly (2009-05-20)
|
